Dr. Motzer on the Milestone of Immunotherapy in RCC – OncLive
OncLive |
Dr. Motzer on the Milestone of Immunotherapy in RCC
OncLive However, the addition of VEGF-targeted therapies, mTOR inhibitors, and immunotherapy agents have brought this landscape up to a new level and changed RCC into a chronic disease, Motzer says. Immunotherapy has allowed for a giant step forward in … |
